Johnson & Johnson (NYSE:JNJ) Shares Sold by AMF Tjanstepension AB

AMF Tjanstepension AB trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,870 shares of the company's stock after selling 25,024 shares during the period. AMF Tjanstepension AB's holdings in Johnson & Johnson were worth $19,729,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. AlphaCore Capital LLC lifted its stake in shares of Johnson & Johnson by 86.4% in the 1st quarter. AlphaCore Capital LLC now owns 20,819 shares of the company's stock worth $3,453,000 after acquiring an additional 9,650 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Johnson & Johnson by 11.8% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,511,914 shares of the company's stock worth $747,939,000 after acquiring an additional 476,245 shares during the period. Accuvest Global Advisors acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $1,029,000. WealthPlan Investment Management LLC lifted its stake in shares of Johnson & Johnson by 2.4% in the 1st quarter. WealthPlan Investment Management LLC now owns 58,311 shares of the company's stock worth $9,670,000 after acquiring an additional 1,361 shares during the period. Finally, One Degree Advisors Inc acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $206,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.5%

JNJ stock opened at $171.41 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $172.18. The company's 50 day simple moving average is $158.89 and its 200-day simple moving average is $157.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $412.81 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.17 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.82 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group increased their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.